Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
3(75.0%)
N/A
1(25.0%)
4Total
Early Phase 1(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04502277Early Phase 1Unknown

Bioavailability of Flucanazole

Role: lead

NCT04113772Not ApplicableUnknown

Bio Equivalency 20 Mgm Orfadin and 20 Mgm of Nitisonine

Role: lead

NCT03975374Early Phase 1Unknown

To Study Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension

Role: lead

NCT03975205Early Phase 1Unknown

To Study the Concentration Level of, Doxil, and Doxorubicin at Various Time Frames

Role: lead

All 4 trials loaded